ROBERT B DARNELL, MD
Neurology at York Ave, New York, NY
License number
New York 168298
Category
Neurology
Type
Neurology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(212) 639-2000
Professional information
Dr. Robert Darnell, New York NY - MD (Doctor of Medicine)
Specialties:
Neurology, Neuropsychiatry (Neurology)
Address:
MEMORIAL NEUROLOGY GROUP
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
Certifications:
Neurology, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Washington University In St Louis School Of Medicine
Graduated: 1985
Mount Sinai Hospital
Cornell U Med Ctr
Washington University In St Louis School Of Medicine
Graduated: 1985
Mount Sinai Hospital
Cornell U Med Ctr
President And Scientific Director, Ny Genome Center; Heilbrunn Professor, Rockefeller University; Investigator, Hhmi
Position:
President and Scientific Director at New York Genome Center, Investigator at Howard Hughes Medical Institute, Professor and Investigator, HHMI at Rockefeller University, Attending Neurologist at Memorial Sloan-Kettering Cancer Center
Location:
United States
Industry:
Research
Work:
New York Genome Center
- New York, NY since Nov 2012
-
President and Scientific Director
Howard Hughes Medical Institute
since 2002
-
Investigator
Rockefeller University
since Nov 1992
-
Professor and Investigator, HHMI
Memorial Sloan-Kettering Cancer Center
since 1990
-
Attending Neurologist
Weill Cornell Medical College
1989 - 1990
-
Chief Resident, Neurology
Education:
Washington University in St. Louis School of Medicine 1979 - 1985
MD, PhD, Molecular Biology Columbia University in the City of New York 1975 - 1979
BA, Biology, Chemistry
MD, PhD, Molecular Biology Columbia University in the City of New York 1975 - 1979
BA, Biology, Chemistry
Interests:
biotechnology; RNA maps; tumor immunity; paraneoplastic neurologic disorders; high throughput RNA profiling, triathlons
Honor & Awards:
NIH Directors Transformative Research Award, 2012
Cotzias Lecture, American Academy of Neurology, 2012
Elected Member, Institute of Medicine of the National Academies, 2010
Elected Fellow (Neuroscience), American Association for the Advancement of Science, 2010
Neuron Innovator Award, GeneExpression Systems, 2010
Elected Member, Association of American Physicians, 2010
Dana Alliance for Brain Initiatives, 2007
Investigator, Howard Hughes Medical Institute, 2002
Elected Member, Kunkel Society, 2001
Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, 2000
Derek Denny-Brown Young Neurological Scholar Award, 1998
Irma T. Hirschl Career Scientist Award, 1996
Languages:
French
Robert B Darnell, New York NY
Specialties:
Neurologist
Address:
1275 York Ave, New York, NY 10065
Education:
Washington University, School of Medicine - Doctor of Medicine
Washington University in St. Louis - Doctor of Philosophy
New York Presbyterian Hospital/Weill Cornell Medical Center - Residency - Neurology
Mount Sinai Hospital, The - Residency - Internal Medicine
Washington University in St. Louis - Doctor of Philosophy
New York Presbyterian Hospital/Weill Cornell Medical Center - Residency - Neurology
Mount Sinai Hospital, The - Residency - Internal Medicine
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Ri Fusion Antigen Recognized By Antibodies Associated With Paraneoplastic Opsoclonus And Methods Of Use Thereof
US Patent:
5614371, Mar 25, 1997
Filed:
Jan 26, 1994
Appl. No.:
8/187793
Inventors:
Jerome B. Posner - New York NY
Robert B. Darnell - New York NY
Henry M. Furneaux - New York NY
Robert B. Darnell - New York NY
Henry M. Furneaux - New York NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
G01N 33579, C07K 1447, C07K 1900, C07K 14705
US Classification:
435 723
Abstract:
An isolated nucleic acid sequence encoding Ri paraneoplastic antigenic polypeptide is provided by this invention. This invention also provides a purified Ri antigenic polypeptide and compositions containing the purified Ri antigenic polypeptide. Further provided by this invention is a antibody directed to an epitope on the Ri paraneoplastic antigenic polypeptide. Compositions containing this antibody also are provided by this invention. This invention also provides methods of diagnosis and treatment using the compositions described hereinabove.
Method Of Purifying Rna Binding Protein-Rna Complexes
US Patent:
2005022, Oct 13, 2005
Filed:
Oct 25, 2004
Appl. No.:
10/971736
Inventors:
Robert Darnell - New York NY, US
Kirk Jensen - Maryland, AU
Jernej Ule - New York NY, US
Kirk Jensen - Maryland, AU
Jernej Ule - New York NY, US
International Classification:
C12Q001/68, C12P019/34
US Classification:
435006000, 435091200
Abstract:
The present invention provides methods for purifying RNA molecules interacting with an RNA binding protein (RBP), and the use of such methods to analyze a gene expression profile of a cell. The invention also provides sequences of RNA molecules that mediate binding to an RBP, proteins encoded by the sequences, a method of identifying the sequences, and the use of the sequences in a screen to identify bioactive molecules. The invention also provides RNA motifs found among the sequences and compounds that bind the RNA motifs. In addition, the invention provides methods of treating diseases associated with a function of an RNA binding protein.
Method Of Purifying Rna Binding Protein-Rna Complexes
US Patent:
2011007, Mar 31, 2011
Filed:
Jul 27, 2009
Appl. No.:
12/509856
Inventors:
Robert Darnell - New York NY, US
Kirk Jensen - Stirling, AU
Jernej Ule - Sawton, GB
Kirk Jensen - Stirling, AU
Jernej Ule - Sawton, GB
Assignee:
THE ROCKEFELLER UNIVERSITY - New York NY
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention provides methods for purifying RNA molecules interacting with an RNA binding protein (RBP), and the use of such methods to analyze a gene expression profile of a cell. The invention also provides sequences of RNA molecules that mediate binding to an RBP, proteins encoded by the sequences, a method of identifying the sequences, and the use of the sequences in a screen to identify bioactive molecules. The invention also provides RNA motifs found among the sequences and compounds that bind the RNA motifs. In addition, the invention provides methods of treating diseases associated with a function of an RNA binding protein.
Methods And Compositions For Tumor Vaccination And Therapy
US Patent:
7928190, Apr 19, 2011
Filed:
Jul 7, 2008
Appl. No.:
12/168629
Inventors:
Robert B. Darnell - New York NY, US
International Classification:
A61K 38/08
US Classification:
530328
Abstract:
The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e. g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.
Methods And Compositions For Tumor Vaccination And Therapy
US Patent:
8193313, Jun 5, 2012
Filed:
Mar 14, 2011
Appl. No.:
13/046875
Inventors:
Robert B. Darnell - New York NY, US
Assignee:
The Rockefeller University - New York NY
International Classification:
A61K 38/08
US Classification:
530328
Abstract:
The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e. g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.
Methods And Compositions For Tumor Vaccination And Therapy
US Patent:
8541547, Sep 24, 2013
Filed:
May 7, 2012
Appl. No.:
13/465391
Inventors:
Robert B. Darnell - New York NY, US
Assignee:
The Rockefeller University - New York NY
International Classification:
A61K 38/08
US Classification:
530328
Abstract:
The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e. g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.